Skip to main content
SpringerLink
Log in

Renal Protection and Antihypertensive Drugs

Current Status

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The renal protective effect of antihypertensive drugs is linked to 2 mechanisms. First, reduction in blood pressure (BP) is a fundamental prerequisite common to all antihypertensive drugs. The exact definition of the level to which BP should be reduced remains to be established, although there is some evidence that BP should be reduced below 130/85mm Hg in patients with diabetic and non-diabetic nephropathies and below 125/75mm Hg in patients with nondiabetic nephropathies and proteinuria >1 g/day However, available data suggest that tight BP control (BP < 140/80mm Hg) can reduce the risk of cardiovascular complications in hypertensive patients with type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus; NIDDM). Secondly, intrarenal actions on mechanisms such as glomerular hypertension and hypertrophy, proteinuria, mesangial cell proliferation, mesangial matrix production and probably endothelial dysfunction, which can cause and/or worsen renal failure, are relevant for the renal protective action of some drug classes. ACE inhibitors possess such properties and also seem to lower proteinuria more than other antihypertensive drugs, despite a similar BP lowering effect. Calcium antagonists likewise exert beneficial intra-renal effects, but with some differences among subclasses. It remains to be evaluated whether angiotensin II-receptor antagonists can exert intrarenal effects and antiproteinuric actions similar to those of ACE inhibitors.

While primary prevention of diabetic nephropathy is still an unsolved problem, there is convincing evidence that in patients with type 1 (insulin-dependent diabetes mellitus; IDDM) or 2 diabetes mellitus and incipient nephropathy ACE inhibitors reduce urinary albumin excretion and slow the progression to overt nephropathy. Similar effects have been reported with some long-acting dihydropyridine calcium antagonists, although less consistently than with ACE inhibitors. In patients with diabetic overt nephropathy, ACE inhibitors and nondihydropyridine calcium antagonists are particularly effective in reducing proteinuria and both drugs can slow the decline in glomerular filtration rate more successfully than other antihypertensive treatment.

Available data in patients with nondiabetic nephropathies indicate that ACE inhibitors can be beneficial, principally in patients with significant proteinuria, in slowing the progression of renal failure. However, it is still unclear whether this beneficial effect of ACE inhibitors is particularly evident in patients with mild and/or more advanced renal failure and whether calcium antagonists possess a similar nephroprotective effect.

Overall, data from clinical trials thus seem to indicate that ACE inhibitors and possibly calcium antagonists should be preferred in the treatment of patients with diabetic and nondiabetic nephropathies. However, further information is needed to understand renal protection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. United States Renal Data System 1997 Annual Report. Incidence and prevalence of ESRD. Am J Kidney Dis 1997; 30 Suppl. 2: S40-53

    Google Scholar 

  2. Vanrenterghen Y, Jones EH. Report on management of renal failure in Europe, XXVI, 1995: report based on the Centre Questionnaire. The ERA-EDTA Registry. Nephrol Dial Transplant 1996; 11 Suppl. 7: 28–32

    Article  Google Scholar 

  3. Simeon G, Bakris GL. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens 1997; 15 Suppl. 2: S77–82

    CAS  Google Scholar 

  4. Parving H-H. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996; 14 Suppl. 2: S89–94

    Article  CAS  Google Scholar 

  5. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15

    Article  PubMed  CAS  Google Scholar 

  6. Baba T, Neugebauer S, Watanabe T. Diabetic nephropathy: its relationship to hypertension and means of pharmacological intervention. Drugs 1997; 54: 197–234

    Article  PubMed  CAS  Google Scholar 

  7. Goa KL, Haria M, Wilde MI. Lisinopril: a review of its pharmacology and use in the management of the complications of diabetes mellitus. Drugs 1997; 53: 1081–105

    Article  PubMed  CAS  Google Scholar 

  8. Rosansky SJ, Hoover DR, King L, et al. The association of blood pressure levels and change in renal function in hypertensive and non hypertensive subjects. Arch Intern Med 1990; 150: 2073–6

    Article  PubMed  CAS  Google Scholar 

  9. Perneger TV, Nieto J, Whelton PK, et al. A prospective study of blood pressure and serum creatinine: results from the ‘Clue’ study and the ARIC study. JAMA 1993; 269: 488–93

    Article  PubMed  CAS  Google Scholar 

  10. Mountokalakis TD. The renal consequences of arterial hypertension. Kidney Int 1997; 51: 1639–53

    Article  PubMed  CAS  Google Scholar 

  11. Zucchelli P, Zuccalà A. The kidney as a victim of essential hypertension. J Nephrol 1997; 10: 203–6

    PubMed  CAS  Google Scholar 

  12. Epstein M. Diabetes and hypertension: bad companions. J Hypertens 1997; 15 Suppl. 2: S55–62

    CAS  Google Scholar 

  13. Oldrizzi L, Rugiu C, Maschio G. Hypertension and progression of renal failure in patients on protein-restricted diet. Contrib Nephrol 1987; 54: 134–43

    PubMed  CAS  Google Scholar 

  14. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670–4

    Article  PubMed  CAS  Google Scholar 

  15. Mogensen CE. Management of the diabetic patient with elevated blood pressure or renal disease. Early screening and treatment programs: albuminuria and blood pressure. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 2335–65

    Google Scholar 

  16. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8

    Article  PubMed  CAS  Google Scholar 

  17. Maschio G, Marcantoni C. Progressive renal damage in essential hypertension. High Blood Press 1997; 6: 65–7

    Google Scholar 

  18. Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens 1997; 15: 451–6

    Article  PubMed  CAS  Google Scholar 

  19. Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164–73

    PubMed  CAS  Google Scholar 

  20. Salvetti A, Giovannetti R, Arrighi P, et al. What effect does blood pressure control have on the progression toward renal failure? Am J Kidney Dis 1993; 21 Suppl. 3: 10–5

    PubMed  CAS  Google Scholar 

  21. Epstein ME, Bakris G. Newer approaches to antihypertensive therapy. Arch Intern Med 1996; 156: 1969–78

    Article  PubMed  CAS  Google Scholar 

  22. Epstein M. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Ren Fail 1996; 18(6): 813–32

    Article  PubMed  CAS  Google Scholar 

  23. Rodicio JL. Does antihypertensive therapy protect the kidney in essential hypertension? J Hypertens 1996; 14 Suppl. 2: S69–76

    Article  CAS  Google Scholar 

  24. van Hooft IMS, Grobbee DE, Derkx FHM, et al. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991; 324: 1305–11

    Article  PubMed  Google Scholar 

  25. Pedrinelli R, Magagna A, Arzilli F, et al. Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension. Clin Pharmacol Ther 1980; 28: 722–31

    Article  PubMed  CAS  Google Scholar 

  26. Benstein JA, Dworkin LD. Renal vascular effects of calcium channel blockers in hypertension. Am J Hypertens 1990; 3: S305–12

    Google Scholar 

  27. Salvetti A. Newer ACE inhibitors: a look at the future. Drugs 1990; 40: 800–28

    Article  PubMed  CAS  Google Scholar 

  28. Burnier M, Brunner HR. Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 1994; 3: 537–45

    Article  PubMed  CAS  Google Scholar 

  29. deLeeuw PW, Birkenhäger WH. Renal hemodynamics and glomerular filtration in essential hypertension: effects of treatment. In: Hansson L, Birkenhäger WH, editors. Hand book of hypertension: assessment of hypertensive organ damage. Amsterdam: Elsevier Science, 1997: 345–63

    Google Scholar 

  30. Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol 1995; 35: 73–80

    PubMed  CAS  Google Scholar 

  31. Meyer TW, Baboolal K, Brenner BM. Nephron adaptation to renal injury. In: Brenner BM, editor. The kidney. Philadelphia: WB Saunders Company, 1996: 2011–48

    Google Scholar 

  32. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793–800

    Article  PubMed  CAS  Google Scholar 

  33. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583–96

    Article  CAS  Google Scholar 

  34. Geza S, Abraham G. Angiotensin II administration as an experimental model of hypertension. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 1423–35

    Google Scholar 

  35. Hemmelder MH, de Zeeuw D, Gansevoort RT, et al. Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney Int 1996; 49: 174–80

    Article  PubMed  CAS  Google Scholar 

  36. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes versus hypertrophy in experimental glomerular sclerosis. Kidney Int 1989; 35: 654–60

    Article  PubMed  CAS  Google Scholar 

  37. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000

    Article  PubMed  CAS  Google Scholar 

  38. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–30

    Article  PubMed  CAS  Google Scholar 

  39. Dworkin LD, Benstein JA, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808–14

    Article  PubMed  CAS  Google Scholar 

  40. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993; 153: 2426–35

    Article  PubMed  CAS  Google Scholar 

  41. Imanishi M, Yoshioka K, Okumura M, et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int 1997; 52 Suppl. 63: S198–200

    Google Scholar 

  42. Mimran A, Insua A, Ribstein J, et al. Contrasting effects of captopril and nifedipine in normotensive patients with diabetic nephropathy. J Hypertens 1988; 6: 919–23

    Article  PubMed  CAS  Google Scholar 

  43. Kon V, Fogo A, Ichikawa I, et al. Bradikinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545–50

    Article  PubMed  CAS  Google Scholar 

  44. Komers R, Cooper ME. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol 1995; 37: F588–94

    Google Scholar 

  45. Lafayette RA, Mayer G, Park SK, et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766–71

    Article  PubMed  CAS  Google Scholar 

  46. Pollock DM, Divish BJ, Polakowski JS, et al. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993; 267: 657–63

    PubMed  CAS  Google Scholar 

  47. Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int 1997; 52 Suppl. 63: S67–70

    Google Scholar 

  48. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–7

    Article  PubMed  CAS  Google Scholar 

  49. Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267–73

    Article  PubMed  CAS  Google Scholar 

  50. Hansen HP, Rossing P, Tarnow L, et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995; 47: 1726–31

    Article  PubMed  CAS  Google Scholar 

  51. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684–92

    Article  PubMed  CAS  Google Scholar 

  52. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793–7

    Article  PubMed  CAS  Google Scholar 

  53. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995; 123: 754–62

    PubMed  CAS  Google Scholar 

  54. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to Ang II. Am J Physiol 1989; 256: F1015–20

    PubMed  CAS  Google Scholar 

  55. Brown SA, Walton CL, Crawford P, et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210–8

    Article  PubMed  CAS  Google Scholar 

  56. Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 1991; 17: 288–95

    Article  PubMed  CAS  Google Scholar 

  57. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 12: 2244–50

    Article  PubMed  CAS  Google Scholar 

  58. Murakami K, Kimura G, Imanishi M, et al. Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. Blood Press 1992; 1 Suppl. 3: 114–8

    Google Scholar 

  59. ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of non-diabetic chronic renal disease. Arch Intern Med 1994; 154: 1185–202

    Article  PubMed  Google Scholar 

  60. Amann K, Irzyniec T, Mall G, et al. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis. J Hypertens 1993; 11: 969–75

    Article  PubMed  CAS  Google Scholar 

  61. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384–94

    Article  PubMed  CAS  Google Scholar 

  62. Mayer G, Lafayette RA, Oliver J, et al. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993; 43: 346–53

    Article  PubMed  CAS  Google Scholar 

  63. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int 1997; 51: 850–4

    Article  PubMed  CAS  Google Scholar 

  64. Williams JD, Coles GA. Proteinuria-A direct cause of renal morbidity? Kidney Int 1994; 45: 443–50

    Article  PubMed  CAS  Google Scholar 

  65. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1971; 31: 673–89

    Article  Google Scholar 

  66. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; I: 1430–42

    Article  Google Scholar 

  67. Hunt LP, Short CD, Mallick NP. Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 1988; 34: 382–8

    Article  PubMed  CAS  Google Scholar 

  68. Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988; 252: 343–54

    Google Scholar 

  69. Jungers P, Hannedouche T, Itakura Y, et al. Progression rate to end-stage renal failure in non-diabetic kidney disease: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995; 10: 1353–60

    PubMed  CAS  Google Scholar 

  70. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 1996; 11: 461–7

    Article  PubMed  CAS  Google Scholar 

  71. Locatelli F, Manzoni C, Marcelli D. Factors affecting progression of renal insufficiency. Miner Electrolyte Metab 1997; 23: 301–5

    PubMed  CAS  Google Scholar 

  72. Ruggenenti P, Perna A, Mosconi L, et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. Kidney Int 1997; 52 Suppl. 63: S54–7

    Google Scholar 

  73. Praga M, Hernandez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting-enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20: 240–8

    PubMed  CAS  Google Scholar 

  74. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993; 22: 202–6

    PubMed  CAS  Google Scholar 

  75. Apperloo AJ, deZeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int 1994; 45 Suppl. 45: S174–8

    CAS  Google Scholar 

  76. Rossing P, Hommel E, Smidt UM, et al. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45 Suppl. 45: S145–9

    CAS  Google Scholar 

  77. Kamper A-L, Strandgaard S, Leyssac PP. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure: hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995; 10: 1182–8

    PubMed  CAS  Google Scholar 

  78. Barnas U, Schmidt A, Haas M, et al. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996; 11: 1822–4

    Article  PubMed  CAS  Google Scholar 

  79. Kasiske BL; Kalil RSN, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–38

    PubMed  CAS  Google Scholar 

  80. Weidmann P, Böehlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993; 8: 582–4

    PubMed  CAS  Google Scholar 

  81. Böhlen L, deCourten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: S84–92

    Google Scholar 

  82. Maki DD, Ma JZ, Louis TA, et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073–80

    Article  PubMed  CAS  Google Scholar 

  83. Weidmann P, Schneider M, Böhlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10 Suppl. 9: 39–45

    PubMed  Google Scholar 

  84. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963–74

    PubMed  CAS  Google Scholar 

  85. Morelli E, Loon N, Meyer T, et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76–82

    Article  PubMed  CAS  Google Scholar 

  86. Remuzzi A, Ruggenenti P, Mosconi L, et al. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993; 6: 36–43

    Google Scholar 

  87. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of Captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–20

    Article  PubMed  CAS  Google Scholar 

  88. Hommel E, Parving H-H, Mathiesen E, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. BMJ 1986; 293: 467–70

    Article  PubMed  CAS  Google Scholar 

  89. Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–9

    Article  PubMed  CAS  Google Scholar 

  90. Kohara K, Mikami H, Okuda N, et al. Angiotensin blockade and progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993; 21: 975–9

    Article  PubMed  CAS  Google Scholar 

  91. Fornes P, Richer C, Vacher E, et al. Losartan’s protective effect in stoke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22(2): 305–13

    Article  PubMed  CAS  Google Scholar 

  92. Tanaka R, Kon V, Yoshioka T, et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45: 537–43

    Article  PubMed  CAS  Google Scholar 

  93. Hutchinson BW, Webster SK. Effect of Ang II receptor antagonist on albuminuria and renal function in passive Heimann nephritis. Am J Physiol 1992; 263: F311–8

    PubMed  CAS  Google Scholar 

  94. Zoccali C, Valvo E, Russo D, et al. Antiproteinuric effect of losartan in patients with chronic renal diseases. Nephrol Dial Transplant 1997; 12: 234–5

    Article  PubMed  CAS  Google Scholar 

  95. Zoja C, Corna D, Facchinetti D, et al. Combining ACE inhibition and angiotensin II receptor blocking stop renal disease progression in experimental membranous nephropathy [abstract]. J Am Soc Nephrol 1995; 6: 860

    Google Scholar 

  96. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707–8

    PubMed  CAS  Google Scholar 

  97. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50: 1641–50

    Article  PubMed  CAS  Google Scholar 

  98. Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481–7

    Article  PubMed  CAS  Google Scholar 

  99. Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensive: a crossover study. J Hypertens 1987; 5 Suppl. 4: S139–42

    Article  CAS  Google Scholar 

  100. Kanayama N, Tsujimura R, She L, et al. Cold-induced stress stimulates the sympathetic nervous system, acusing hypertension and proteinuria in rats. J Hypertens 1997; 15: 383–9

    Article  PubMed  CAS  Google Scholar 

  101. Poulsen PL, Ebbehøj E, Hansen KW, et al. 24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia 1997; 40: 718–25

    Article  PubMed  CAS  Google Scholar 

  102. Mølgaard H, Christensen PD, Sørensen KE, et al. Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients. Diabetes 1992; 41: 812–7

    Article  PubMed  Google Scholar 

  103. Weinrauch LA, Kennedy FP, Geason RE, et al. Relationship between autonomic function and progression of renal disease in diabetic proteinuria. Am J Hypertens 1998; 11: 302–8

    Article  PubMed  CAS  Google Scholar 

  104. Fogari R, Zoppi A, Lusardi P, et al. Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function [abstract]. J Hypertens 1996; 14 Suppl. 1: S193

    Google Scholar 

  105. Lusardi P, Corradi L, Pasotti C, et al. Effects of amlodopine vs fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes [abstract]. J Hypertens 1996; 14 Suppl. 1: S193

    Google Scholar 

  106. Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989; 14: 851–5

    Article  PubMed  CAS  Google Scholar 

  107. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41: 912–9

    Article  PubMed  CAS  Google Scholar 

  108. Fogari R, Zoppi A, Mugellini A, et al. Effect of benazepril plus amlodipine vs benazepril alone on urinary albumin excretion in hypertensive patients with type II diabetes and microalbuminuria. Clin Drug Invest 1997; 13 Suppl. 1: S50–5

    Article  Google Scholar 

  109. Raij L. Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Nephrol Dial Transplant 1995; 10 Suppl. 9: S23–7

    Google Scholar 

  110. Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. Boca Raton: CRC Press, 1990

    Google Scholar 

  111. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20–32

    Article  PubMed  CAS  Google Scholar 

  112. Mattei P, Virdis A, Ghiadoni L, et al. Endothelial function in hypertension. J Nephrol 1997; 10: 193–8

    Google Scholar 

  113. Rabelink TJ, Koomans HA. Endothelial function and the kidney: an emerging target for cardiovascular therapy. Drugs 1997; 53 Suppl. 1: 11–9

    Article  PubMed  CAS  Google Scholar 

  114. Remuzzi G, Benigni A. Progression of proteinuric diabetic and nondiabetic renal diseases: a possible role for renal endothelin. Kidney Int 1997; 51 Suppl. 58: S66–8

    Google Scholar 

  115. Mimran A, Ribstein J, DuCailar G. Contrasting effect of anti-hypertensive treatment on the renal response to L-Arginine. Hypertension 1995; 26: 937–41

    Article  PubMed  CAS  Google Scholar 

  116. Higashi Y, Oshima T, Ozono R, et al. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995; 25: 898–902

    Article  PubMed  CAS  Google Scholar 

  117. Higashi Y, Oshima T, Watanabe M, et al. Renal response to L-arginine in salt-sensitive patients with essential hypertension. Hypertension 1996; 27: 643–8

    Article  PubMed  CAS  Google Scholar 

  118. Taddei S, Virdis A, Ghiadoni L, et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16: 447–56

    Article  PubMed  CAS  Google Scholar 

  119. Dijkhorst-Oei LT, Rabelink TJ, Boer P, et al. Nifedipine attenuates systemic and renal vasoconstriction during nitric oxide inhibition in humans. Hypertension 1997; 29: 1192–8

    Article  PubMed  CAS  Google Scholar 

  120. Taddei S, Virdis A, Ghiadoni L, et al. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30; 1606–12

    Article  PubMed  CAS  Google Scholar 

  121. Taddei S, Virdis A, Ghiadoni L, et al. Nifedipine enhances endothelimu-dependent relaxation and ihnibits contractions to endothelin-1 and phenilephrine in human hypertension [abstract]. Circulation 1997; 96: 4275

    Google Scholar 

  122. Madeddu P, Yang X, Anania V, et al. Efficacy of nifedipine to prevent systemic and renal vasoconstrictor effects of endothelin. Am J Physiol 1990; 259: F304–11

    PubMed  CAS  Google Scholar 

  123. Takahashi K, Katoh T, Fukunaga M, et al. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endotehlin. Am Heart J 1993; 125: 609–19

    Article  PubMed  CAS  Google Scholar 

  124. Rabelink TJ, Kaasjager KAH, Boer P, et al. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994; 46: 376–81

    Article  PubMed  CAS  Google Scholar 

  125. Consensus Development Conference on the treatment of hypertension in diabetes. Treatment of hypertension in diabetes. Diabetes Care 1993; 16: 1394–401

    Google Scholar 

  126. World Health Organization/International Society of Hypertension. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905–18

    Article  Google Scholar 

  127. World Health Organization Expert Committee. Hypertension control. Geneva: World Health Organization, 1996

    Google Scholar 

  128. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46

    Google Scholar 

  129. Ruilope LM, Garcia-Robles R. How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997; 15 Suppl. 2: S63–5

    CAS  Google Scholar 

  130. Rodby RA, Rohde R, Evans J, et al. The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. J Am Soc Nephrol 1995; 5: 1775–81

    PubMed  CAS  Google Scholar 

  131. Bain R, Rohde R, Hunsicker LG, et al. A controlled clinical trial of angiotensin-converting enzyme inhibition in type 1 diabetic nephropathy: study design and patients chracteristics. J Am Soc Nephrol 1992; 3: S97–103

    PubMed  CAS  Google Scholar 

  132. Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996; 39: 1646–54

    Article  PubMed  CAS  Google Scholar 

  133. Mehler PS, Jeffers BW, Estacio R, et al. Associations of hypertension and complications in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997; 10: 152–61

    Article  PubMed  CAS  Google Scholar 

  134. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) study-patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press 1994; 3: 322–7

    Article  PubMed  CAS  Google Scholar 

  135. Jamerson K. The effect of blood pressure reduction on end stage renal disease. Am J Hypertens 1996; 9: S60–4

    Article  Google Scholar 

  136. Oldrizzi L, Rugiu C, De Biase V, et al. The place of hypertension among the risk factors for renal function in chronic renal failure. Am J Kidney Dis 1993; 21 Suppl. 2: 119–23

    PubMed  CAS  Google Scholar 

  137. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–84

    Article  PubMed  CAS  Google Scholar 

  138. Levey AS, Bosch JP, Coggins CH, et al. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1996; 7: 556–65

    CAS  Google Scholar 

  139. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908–19

    Article  PubMed  CAS  Google Scholar 

  140. Lazarus JM, Bourgoignie JJ, Buckalew VM, The Modification of Diet in Renal Disease Study Group, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997; 29: 641–50

    Article  PubMed  CAS  Google Scholar 

  141. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997; 30: 428–35

    Article  PubMed  CAS  Google Scholar 

  142. Wright JT, Kusec JW, Toto RD, et al. Design and baseline characteristics of participants in the African-American Study of Kidney disease and hypertension (AASK) Pilot study. Control Clin Trials 1996; 17 Suppl. 4: S3–16

    Article  Google Scholar 

  143. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–92

    Article  Google Scholar 

  144. Chan JCN, Cockram CS, Nicholls MG, et al. Comparison of enalapril and nifedipine in treating non-insulin-dependent diabetes associated with hypertension: one year analysis. BMJ 1992; 305: 981–5

    Article  PubMed  CAS  Google Scholar 

  145. Lacourcière Y, Nadeau A, Poirier L, et al. Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension 1993; 21: 786–94

    Article  PubMed  Google Scholar 

  146. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216–22

    Article  PubMed  CAS  Google Scholar 

  147. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303–7

  148. Mathiesen ER, Hommel E, Smith U, et al. Efficacy of captopril in normotensive diabetic patients with microalbuminuria 8 years follow up [abstract]. Diabetologia 1995; 38: A46

    Article  Google Scholar 

  149. Crepaldi G, Carta Q, DeFerrari G, et al. Effects of lisinopril and nifedipine on the progression to overt proteinuria in insulin-dependent diabetic patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21(1): 104–10

    Article  PubMed  CAS  Google Scholar 

  150. Nielsen S, Schmitz A, Rehling M, et al. Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes. Diabetes Care 1993; 16: 1427–32

    Article  PubMed  CAS  Google Scholar 

  151. Bilo H, Kluitman E, van Ballegooie E, et al. Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus. Diabetes Res 1993; 23: 115–2

    PubMed  CAS  Google Scholar 

  152. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275–9

    Article  PubMed  CAS  Google Scholar 

  153. Schnack C, Capek M, Banyai M, et al. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 1994; 31: 14–8

    Article  PubMed  CAS  Google Scholar 

  154. Laffel LMB, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995: 99: 497–593

    Article  PubMed  CAS  Google Scholar 

  155. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587–93

    Article  Google Scholar 

  156. Hallab M, Gallois Y, Chatellier G, et al. Comparison of reduction in microalbuminuria by enlapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ 1993; 306: 175–82

    Article  PubMed  CAS  Google Scholar 

  157. Salvetti A, Virdis A, Taddei S, et al. Trough: peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study. J Hypertens 1996; 14: 661–7

    Article  PubMed  CAS  Google Scholar 

  158. Fioretto P, Frigato F, Velussi M, et al. Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992; 5: 837–46

    PubMed  CAS  Google Scholar 

  159. Ravid M, Savin H, Jutrin I, et al. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994; 45 Suppl. 45: S161–4

    CAS  Google Scholar 

  160. Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin-converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 1989; 32: 40–4

    PubMed  CAS  Google Scholar 

  161. Ruggenenti P, Mosconi L, Bianchi L, et al. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 1994; 24: 753–61

    PubMed  CAS  Google Scholar 

  162. Agardh CD, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185–92

    PubMed  CAS  Google Scholar 

  163. Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 1996; 49 Suppl. 55: S91–3

    Google Scholar 

  164. Piñol C, Cobos A, Cases A, et al. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. Kidney Int 1996; 49 Suppl. 55: S85–7

    Google Scholar 

  165. Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092–5

    Article  PubMed  CAS  Google Scholar 

  166. O’Donnel MJ, Rowe BR, Lawson N, et al. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993; 7: 327–32

    Google Scholar 

  167. Bretzel RG, Bollen CC, Maeser E, et al. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993; 21 Suppl. 3: 53–64

    PubMed  CAS  Google Scholar 

  168. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210–6

    Article  Google Scholar 

  169. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150–5

    Article  PubMed  CAS  Google Scholar 

  170. Stornello M, Valvo EV, Vasquez E, et al. Systemic and renal effects of chronic angiotensin converting enzyme inhibition with captopril in hypertensive diabetic patients. J Hypertens Suppl 1989; 7(7): S65–7

    PubMed  CAS  Google Scholar 

  171. Valvo E, Bedogna V, Casagrande P, et al. Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med 1988; 85: 344–8

    Article  PubMed  CAS  Google Scholar 

  172. Parving H-H, Hommel E, Nielsen MD, et al. Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. BMJ 1989; 299: 533–6

    Article  PubMed  CAS  Google Scholar 

  173. Holdaas H, Hartmann A, Lien MG, et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163–70

    Article  PubMed  CAS  Google Scholar 

  174. Björck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–43

    Article  PubMed  Google Scholar 

  175. De Cesaris R, Ranieri G, Filitti V, et al. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol 1993; 22: 208–14

    Article  PubMed  Google Scholar 

  176. Elving LD, Wetzeis JFM, van Lier HJJ, et al. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994; 37: 604–9

    Article  PubMed  CAS  Google Scholar 

  177. Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press 1993; 2: 301–8

    Article  PubMed  CAS  Google Scholar 

  178. Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and β-adrenoceptor blockers. Clin Sci 1992; 82: 19–23

    PubMed  CAS  Google Scholar 

  179. Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–7

    Article  PubMed  CAS  Google Scholar 

  180. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113: 987–8

    PubMed  CAS  Google Scholar 

  181. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996; 125: 210–4

    Google Scholar 

  182. Bauer JH, Reams GP, Hewett J, et al. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992; 20: 443–57

    PubMed  CAS  Google Scholar 

  183. Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19 Suppl. 2: 237–42

    Article  Google Scholar 

  184. Nielsen FS, Rossing P, Gall MA, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43: 1108–13

    Article  PubMed  CAS  Google Scholar 

  185. Liou H-H, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal disease. Nephron 1995; 69: 41–8

    Article  PubMed  CAS  Google Scholar 

  186. Fogari R, Zoppi A, Pasotti C, et al. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J Hum Hypertens 1995; 9: 131–5

    PubMed  CAS  Google Scholar 

  187. Nielsen FS, Rossing P, Gall MA et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182–8

    Article  PubMed  CAS  Google Scholar 

  188. Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in african americans. Hypertension 1997; 29: 744–50

    Article  PubMed  CAS  Google Scholar 

  189. Stornello M, Valvo EV, Puglia N, et al. Angiotensin-converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. J Hypertens 1988; 6 Suppl. 4: S464–6

    CAS  Google Scholar 

  190. Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046–51

    Article  PubMed  CAS  Google Scholar 

  191. O’Donnel MJ, Rowe BR, Lawson N, et al. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double blind study. J Hum Hypertens 1993; 7: 333–9

    Google Scholar 

  192. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685–8

    Article  PubMed  CAS  Google Scholar 

  193. Parving H-H, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; I: 1175–8

    Article  Google Scholar 

  194. Parving H-H, Andersen AR, Hommel E, et al. Effect of antihypertensive treatment on kidney function in insulin-dependent diabetic nephropathy. BMJ 1987; 294: 1443–7

    Article  PubMed  CAS  Google Scholar 

  195. Parving H-H, Andersen AR, Smidt UM, et al. Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes 1983; 32 Suppl. 2: 83–7

    PubMed  Google Scholar 

  196. Parving H-H, Andersen AR, Hommel E, et al. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension 1985; 7 Suppl 2: 114–7

    Article  Google Scholar 

  197. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 1988; 297: 1086–91

    Article  PubMed  CAS  Google Scholar 

  198. Baba T, Murabayashi S, Tomiyama T, et al. Uncontrolled hypertension is associated with a radipe progression of nephropathy in type II diabetic patients with proteinuria and presevered renal function. Tohoku J Exp Med 1990; 161: 311–8

    Article  PubMed  CAS  Google Scholar 

  199. Viberti GC. Outcome variables in the assessment of progression of diabetic kidney disease. Kidney Int 1994; 45 Suppl. 45: S121–4

    CAS  Google Scholar 

  200. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62

    Article  PubMed  CAS  Google Scholar 

  201. Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994; 46: 1688–93

    Article  PubMed  CAS  Google Scholar 

  202. Mogensen CE. Microalbuminuria predicts clinical proteinuira and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–60

    Article  PubMed  CAS  Google Scholar 

  203. Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319–25

    Article  Google Scholar 

  204. Sawicki PT, Heise T, Berger M. Antihypertensive treatment and mortality in diabetic patients: what is the evidence? Diabetologia 1997; 40: S134–7

    Article  PubMed  Google Scholar 

  205. Parving H-H, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 99: 230–3

    Article  Google Scholar 

  206. Mathiensen ER, Borch-Johnsen K, Jensen DV, et al. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884–6

    Article  Google Scholar 

  207. Sawicki PT, Mühlhauser I, Didjurgeit U, et al. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995; 13: 933–8

    Article  PubMed  CAS  Google Scholar 

  208. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52

    Article  PubMed  CAS  Google Scholar 

  209. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21(4): 597–603

    Article  PubMed  CAS  Google Scholar 

  210. Hansson L, Hedner T, Lindholm LH, et al. The Captopril Prevention Project (CAPPP) in hypertension-Final results. J Hypertens 1989; 16 Suppl. 2: S22

    Google Scholar 

  211. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62

    Article  PubMed  CAS  Google Scholar 

  212. Kaplan N. J curve not burned off by HOT study. Lancet 1998; 351: 1748–9

    Article  PubMed  CAS  Google Scholar 

  213. Turner R, for theUK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13

    Article  Google Scholar 

  214. Holman R, for the UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20

    Article  Google Scholar 

  215. 1999 World Health Organization. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83

    Google Scholar 

  216. Passa P, Chatellier G, The Diab-Hycar Study Group. The Diab-Hycar Study. Diabetologia 1996; 39: 1662–7

    Article  PubMed  CAS  Google Scholar 

  217. Locatelli F, Alberti D, Graziani G, et al. Factors affecting chronic renal failure progression: results from a multicentre trial. Miner Electrolyte Metab 1992; 18: 295–302

    PubMed  CAS  Google Scholar 

  218. ter Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal diseases. Arch Int Med 1993; 153: 1749–59

    Article  Google Scholar 

  219. Zucchelli P, Zuccalà A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist’s view. Am J Kidney Dis 1993; 21 Suppl. 2: S87–91

    Google Scholar 

  220. Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25: 207–21

    Article  PubMed  CAS  Google Scholar 

  221. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365–77

    Article  PubMed  CAS  Google Scholar 

  222. Fogo A, Breyer JA, Smith MC, et al. Accuracy of diagnosis of hypertensive nephrosclerosis in african americans: a report from the African Americans Study of Kidney Disease (AASK) Trial. Kidney Int 1997; 51: 244–52

    Article  PubMed  CAS  Google Scholar 

  223. Pedrinelli R. Microalbuminuria in hypertension. Nephron 1996; 73: 499–505

    Article  PubMed  CAS  Google Scholar 

  224. Ruilope LM. The kidney and cardiovascular risk. Nephrol Dial Transplant 1997; 12: 243–54

    Article  PubMed  CAS  Google Scholar 

  225. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension. J Nephrol 1997; 10: 216–8

    PubMed  CAS  Google Scholar 

  226. Losito A, Fortunati F, Zampi I, et al. Impaired renal function reserve and albuminuria in essential hypertension. BMJ 1988; 296: 1562–4

    Article  PubMed  CAS  Google Scholar 

  227. Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria in salt-sensitive patients: a marker for renal cardiovascular risk factors. Hypertension 1984; 23: 195–9

    Article  Google Scholar 

  228. Mattei P, Arzilli F, Giovannetti R, et al. Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest 1997; 27: 755–60

    Article  PubMed  CAS  Google Scholar 

  229. Bianchi S, Bigazzi R, Baldari G, et al. Microalbuminuria in patients with essential hypertension: effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens 1991; 4: 291–6

    PubMed  CAS  Google Scholar 

  230. Erley CM, Haefele U, Heyne N, et al. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension 1993; 21: 810–5

    Article  PubMed  CAS  Google Scholar 

  231. Jensen JS, Borch-Johnsen K, Jensen G, et al. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci 1995; 88: 629–33

    PubMed  CAS  Google Scholar 

  232. Puig JG, Mateos FA, Ramos TH, et al. Albumin excretion rate and metabolic modifications in patients with essential hypertension: effects of two angiotensin converting enzyme inhibitors. Am J Hypertens 1994; 7: 46–51

    PubMed  CAS  Google Scholar 

  233. Agrawal B, Wolf K, Berger A, et al. Effects of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1995; 10: 551–5

    Google Scholar 

  234. Sievert-Delle A, Ljungman S, Hartford M, et al. Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 1996; 9: 841–9

    Article  Google Scholar 

  235. Ruilope LM, Alcazar JM Hernandez E, et al. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990; 8: 525–31

    Article  PubMed  CAS  Google Scholar 

  236. Vetter W, Wehling M, Foerster E-C, et al. Long-term effect of captopril on kidney function in various forms of hypertension. Klin Wochenschr 1984; 62: 731–7

    Article  PubMed  CAS  Google Scholar 

  237. Sanchez RA, Traballi CA, Marco EJ, et al. Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure. Drugs 1991; 41 Suppl. 1: 25–30

    Article  PubMed  Google Scholar 

  238. Bauer JH, Reams GP, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 1987; 147: 1397–400

    Article  PubMed  CAS  Google Scholar 

  239. Salvetti A, Giovannetti R, Arrighi P, et al. How to treat the hypertensive patient with early renal damage. Am J Kidney Dis 1993; 21 Suppl. 2: 95–9

    PubMed  CAS  Google Scholar 

  240. Himmelmann A, Hansson L, Hansson B-G, et al. ACE inhibition preserves renal function betterthan β-blockade in the treatment of essential hypertension. Blood Press 1995; 4: 85–90

    Article  PubMed  CAS  Google Scholar 

  241. Aurell M, Bengtsson C, Bjork S. Enalapril versus metoprolol in primary hypertension: effects on the glomerular filtration rate. Nephrol Dial Transplant 1997; 12: 2289–94

    Article  PubMed  CAS  Google Scholar 

  242. Pettinger WA, Lee HC, Reisch J, et al. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766–72

    Article  PubMed  CAS  Google Scholar 

  243. Toto RD, Mitchell HC, Smith RD, et al. ‘Strict’ blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48: 851–9

    Article  PubMed  CAS  Google Scholar 

  244. Pettinger WA, Mitchell HC, Lee HC, et al. Pseudo renal artery stenosis (PRAS) syndrome. Am J Hypertens 1989; 2: 349–51

    PubMed  CAS  Google Scholar 

  245. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45 246.

    Article  PubMed  CAS  Google Scholar 

  246. Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney disease and hypertension pilot study. Am J Kidney Dis 1997; 29: 720–8

    Article  PubMed  CAS  Google Scholar 

  247. Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and β-blocking agent. Nephron 1991; 59: 57–60

    Article  PubMed  CAS  Google Scholar 

  248. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting-enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients reciving treatment with other antihypertensive agents and to patients reciving no therapy. Am J Kidney Dis 1994; 23: 247–54

    PubMed  CAS  Google Scholar 

  249. Feriozzi S, Pierucci A, Roscia E, et al. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens 1989; 7 Suppl. 7: S63–4

    CAS  Google Scholar 

  250. Okamura M, Kanayama Y, Negoro N, et al. Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. In: Morii H, editor. Calcium regulating hormones. I. Role in disease and aging. Contrib Nephrol 1991; 90: 161–5

    Google Scholar 

  251. Bannister KM, Weaver A, Clarkson AR, et al. Effect of angiotensin converting enzyme and calcium channel inhibition on progression of IgA nephropathy. In: Clarkson AR, Woodroffe AJ, editors. IgA nephropathy: pathogenesis and treatment. Contrib Nephrol 1995; 111: 184–93

    Google Scholar 

  252. Rodicio JL, Alcazar JM, Ruilope LM. Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria. Kidney Int 1990; 38: 590–4

    Article  PubMed  CAS  Google Scholar 

  253. Ritz E, Fliser D, Keller H, et al. Are newer antihypertensive agents really more effective than traditional drugs in progressive renal disease? Am J Kidney Dis 1991; 17 Suppl. 1: 76–80

    PubMed  CAS  Google Scholar 

  254. Ferder LF, Inserra F, Daccordi H, et al. Enalapril improved renal function and proteinuria in chronic glomerulopathies. Nephron 1990; 55 Suppl. 1: 90–5

    Article  PubMed  Google Scholar 

  255. Kamper AL, Strangaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomised controlled trial. Am J Hypertens 1992; 5: 423–30

    PubMed  CAS  Google Scholar 

  256. Ambroso GC, Como G, Scalamogna A, et al. Treatment of arterial hypertension with nifedipine in patients with chronic renal insufficiency. Clin Nephrol 1985; 23: 41–5

    PubMed  CAS  Google Scholar 

  257. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37: 1113–9

    Article  PubMed  CAS  Google Scholar 

  258. Eliahou HE, Cohen D, Hellberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988; 8: 285–90

    Article  PubMed  CAS  Google Scholar 

  259. Bianchi S, Bigazzi R, Baldari G, et al. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol 1991; 11: 131–7

    Article  PubMed  CAS  Google Scholar 

  260. Zucchelli P, Zuccalà A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–8

    Article  PubMed  CAS  Google Scholar 

  261. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833–7

    Article  PubMed  CAS  Google Scholar 

  262. vanEssen GG, Apperloo AJ, Rensma PL, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int 1997; 52 Suppl. 63: S58–62

    Google Scholar 

  263. Ihle BU, Whitworth JA, Shahinfar S, et al. Angiotensin converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double blind trial. Am J Kidney Dis 1996; 27: 489–95

    Article  PubMed  CAS  Google Scholar 

  264. The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857–63

    Article  Google Scholar 

  265. Cinotti GA, Zucchelli PC. Effect of lisinopril on the progression of non-diabetic chronic renal failure [abstract]. Nephrol Dial Transplant 1997; 12: A94

    Google Scholar 

  266. Locatelli F, Carbarns IRI, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. Kidney Int 1997; 52 Suppl. 63: S63–6

    Google Scholar 

  267. Ruggenenti P, Perna A, Mosconi L, et al. for The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857–63

    Article  Google Scholar 

  268. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337–45

    PubMed  CAS  Google Scholar 

  269. Maschio G. Protecting the residual renal function: how do ACE inhibitors and calcium antagonists compare. Nephron 1994; 67: 257–62

    Article  PubMed  CAS  Google Scholar 

  270. Navis G, de Zeeuw D, De Jong PE. ACE-inhibitors: panacea for progressive renal disease? Lancet 1997; 349(9069): 1852–3

    Article  PubMed  CAS  Google Scholar 

  271. Arrighi P, Giovannetti R, Mattei P, et al. Comparison of renal hemodynamic effects of four ACE-inhibitors in essential hypertensive patients. Blood Press 1995; 4: 236–41

    Google Scholar 

  272. Salvetti A, Argenio GF, Brogi G, et al. Management of hypertension and metabolic disorders. In: Kaplan NM, editor. Metabolic aspects of hypertension. London: Science Press, 1994; 6.1: 1–19

  273. Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15 Suppl. 2: S67–75

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Medicina Interna, Department of Internal Medicine, University of Pisa, Pisa, Italy, via Roma, 67, 56126, Pisa, Italy

    Antonio Salvetti, Paola Mattei & Isabella Sudano

Authors
  1. Antonio Salvetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Mattei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabella Sudano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Salvetti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salvetti, A., Mattei, P. & Sudano, I. Renal Protection and Antihypertensive Drugs. Drugs 57, 665–693 (1999). https://doi.org/10.2165/00003495-199957050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957050-00002

Keywords

Search

Navigation